Get the Stockscreener App
0.8903
0.58%
0.0051
After Hours:
.89
-0.0003
-0.03%
Genprex Inc stock is traded at $0.8903, with a volume of 371.47K.
It is up +0.58% in the last 24 hours and down -38.60% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$0.8852
Open:
$0.883
24h Volume:
371.47K
Relative Volume:
0.42
Market Cap:
$9.27M
Revenue:
-
Net Income/Loss:
$-16.23M
P/E Ratio:
-0.0598
EPS:
-14.8777
Net Cash Flow:
$-15.31M
1W Performance:
+2.33%
1M Performance:
-38.60%
6M Performance:
-81.02%
1Y Performance:
-93.91%
1-Day Range:
$0.88
$0.9099
1-Week Range:
$0.8713
$1.01
52-Week Range:
$0.8612
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.8903 | 9.22M | 0 | -16.23M | -15.31M | -14.88 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Top 3 Health Care Stocks That Are Set To Fly In Q2 - Benzinga
MSN Money - MSN
GNPX Forecast, Price Target & Analyst Ratings | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatm - GuruFocus
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel - TipRanks
Genprex, Inc. Files Form 8-K With SEC: Company Information, Nasdaq Listing, and Regulatory Details - Minichart
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - BioSpace
Israel grants Genprex (NASDAQ: GNPX) patent for REQORSA lung cancer use - Stock Titan
Genprex (NASDAQ: GNPX) seeks approval for equity plan and reverse stock split - Stock Titan
Genprex collaborators to present diabetes gene therapy data at May meeting By Investing.com - Investing.com Australia
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex collaborators to present diabetes gene therapy data at May meeting - Investing.com UK
average down - Moomoo
Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex (GNPX) shows GPX-002 gene therapy reversed hyperglycemia in T2D mice - Stock Titan
GNPX Should I Buy - Intellectia AI
Genprex biomarker research selected for ASCO 2026 meeting By Investing.com - Investing.com India
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - StreetInsider
Genprex biomarker research selected for ASCO 2026 meeting - Investing.com
Lung cancer gene therapy study lands ASCO slot with biomarker data - Stock Titan
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - The Malaysian Reserve
Genprex signs research deal to study lung cancer biomarkers By Investing.com - Investing.com India
Genprex (GNPX) Partners with MD Anderson for Cancer Research - GuruFocus
Genprex enters research agreement with UT MD Anderson - TipRanks
Genprex (GNPX) Pops As Reqorsa Data Impresses At AACR 2026 - timothysykes.com
Genprex Expands Lung Cancer Gene Therapy Research Collaboration - TipRanks
Genprex signs research deal to study lung cancer biomarkers - Investing.com
Genprex enters MD Anderson research pact to study biomarkers for REQORSA in NSCLC and SCLC - TradingView
Genprex (NASDAQ: GNPX) expands MD Anderson pact and reports Reqorsa lung cancer trial progress - Stock Titan
Genprex presents preclinical lung cancer therapy data at AACR By Investing.com - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - The Malaysian Reserve
Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus
Genprex (GNPX) Reveals Promising Lung Cancer Research at AACR 20 - GuruFocus
Genprex presents preclinical lung cancer therapy data at AACR - Investing.com
Lung cancer gene therapy from Genprex shrank tumors, cleared some in mice - Stock Titan
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting (2026-04-20) - Seeking Alpha
Genprex | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Genprex (NASDAQ: GNPX) asks shareholders to OK 1:5–1:50 reverse split, equity plan - Stock Titan
GNPX News | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex director Longnecker sells shares worth $22 - Investing.com
Genprex director Longnecker sells shares worth $22 By Investing.com - Investing.com Australia
Genprex (GNPX) director logs small stock sales mainly for taxes - Stock Titan
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
Surprises Report: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):